Veeva Systems (NYSE:VEEV) today announced Veeva SiteVault Free, a free eRegulatory solution built specifically for clinical research sites. Veeva SiteVault allows sites to more effectively manage regulatory documents and trial processes to speed study activation and improve investigator site file management. Now all sites can have access to a modern cloud solution to streamline trial activities and accelerate clinical research.
“Veeva aims to simplify study execution so sites can focus on the critical work of clinical research and patient care,” said Peter Gassner, founder and CEO of Veeva. “We’re proud to partner with the clinical research community to help simplify and accelerate the process of getting important medicines to the patients who need them.”
Veeva SiteVault reduces the administrative burden of managing regulatory documents and processes with capabilities such as electronic signatures, remote monitoring, certified copy workflows, and reporting. Veeva SiteVault can be used for all trials regardless of what technology sponsors are using, as well as the site file for investigator initiated trials. Both editions, SiteVault Free and SiteVault Enterprise, support compliance with 21 CFR Part 11 and HIPAA requirements.
SiteVault Free supports an unlimited number of users and comes with full customer support from Veeva.
Planned for availability in December 2019, sites can sign up for SiteVault Free ahead if its release at sites.veeva.com.
SiteVault Enterprise is a fully configurable edition of Veeva SiteVault that includes open APIs for integrations, customized reports, and tailored workflows. SiteVault Enterprise is available today and used by leading research organizations such as IACT Health, Ora, Inc., Penn Medicine, and University of Louisville.
Veeva is the leading provider of clinical operations technology with more than 200 sponsors using Vault eTMF or Vault Study Startup, including 12 of the top 20 global biopharma companies. In the second half of 2020, Veeva plans to enable automated document and data sharing from sites using Veeva SiteVault to sponsors that are using Vault eTMF or Vault Study Startup.
What the Industry is Saying About Veeva SiteVault:
“SCRS applauds Veeva’s site-centric approach. There is a significant opportunity for solution providers to include sites’ perspectives when designing technology,” said Casey Orvin, president at the Society for Clinical Research Sites (SCRS). “When technology solutions reflect site needs, they are more effective in achieving their goal to streamline workflow processes.”
“Veeva is helping sponsors think differently about supporting their clinical research site partners,” said Doug Schantz, executive director, development operations at AstraZeneca. “Veeva SiteVault Free will allow all types of sites to standardize on the same Veeva Vault technology that is widely utilized by their sponsors.”
“There’s a significant opportunity to improve how sites and sponsors collaborate and share information throughout the course of a clinical trial,” said Lale Akca, executive director of the clinical trials unit at the University of Louisville, a leading academic research institution. “Veeva SiteVault Enterprise gives us a flexible solution to support the complexity of research operations at large research hospital systems and run trials faster.”
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.